Toxys

Executive Summary

Toxys is a Dutch biotechnology company founded in 2009 that specializes in innovative, mechanism-based in vitro toxicology testing solutions. Its proprietary platforms, ToxTracker and ReproTracker, provide detailed mechanistic insights into genotoxicity and developmental toxicity, enabling drug developers and chemical safety assessors to make critical decisions while reducing reliance on animal testing. By offering high-content, predictive data, Toxsys supports safer and more efficient compound development pipelines in the pharmaceutical and chemical industries. With its focus on replacing, reducing, and refining animal experiments (the 3Rs), Toxys is well-positioned to benefit from increasing regulatory and societal pressure to adopt non-animal testing methods. The company has established a strong scientific foundation and collaborates with leading research institutions. As regulatory acceptance of in vitro methods grows, Toxys could become a key partner for global drug and chemical developers seeking reliable, mechanism-based safety data. Its continued innovation and strategic partnerships will be critical to capturing market share in the evolving toxicology landscape.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top 20 pharmaceutical company40% success
• Q4 2026Regulatory qualification of ToxTracker by the EMA or FDA30% success
• Q2 2026Launch of a new high-throughput screening service50% success